We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Organic Soils.com announced that it has signed a definitive agreement to acquire
all of the issued and outstanding common stock of Inhibetex Therapeutics, Inc.
(Inhibetex) in a tax-free exchange.
Maxygen announced that it has earned a significant milestone in its collaboration
with Roche to develop improved interferon alpha protein therapeutics to treat
hepatitis C virus (HCV) and hepatitis B virus (HBV) infections.
Baxter Healthcare Corporation and Cangene Corporation
announced that, effective immediately, Baxter has assumed exclusive rights to
market and distribute Cangene's WinRho SDF [Rho(D) Immune Globulin Intravenous
(Human)] in the United States. WinRho SDF is used to treat a critical bleeding
disorder called immune thrombocytopenic purpura (ITP).
Sanofi-aventis has fended off the first of several patent challenges against
its blockbuster stroke medication Plavix, winning a patent suit in Canada, the
company said.
The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC)
has cited Boehringer Ingelheim Pharmaceuticals for running a journal advertisement
containing unsubstantiated superiority claims about its stroke drug Aggrenox.